Experience with Intravesical Adriamycin Therapy of Superficial Bladder Tumors.
- Author:
Young Nam WOO
1
;
Hei Young SHIM
Author Information
1. Department of Urology, College of Medicine, Hanyang University, Seoul, Korea.
- Publication Type:Clinical Trial ; Original Article ; Randomized Controlled Trial
- Keywords:
adriamycin;
bladder tumor
- MeSH:
Doxorubicin*;
Dysuria;
Follow-Up Studies;
Hematuria;
Humans;
Prospective Studies;
Recurrence;
Urinary Bladder Neoplasms*;
Urinary Bladder*
- From:Korean Journal of Urology
1986;27(5):669-675
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
We studied a prospective clinical trial designed to compare the effect of Adriamycin with TUR alone in 27 patients with superficial bladder tumors (stage O, A) who underwent treatment at the Hanyang University Hospital from March, 1981 to February 1985. A total 27 patients were randomly divided into 2 groups. Control group, comprised 11 patients, treated TUR alone and study group, consisted of 16 patients, treated with intravesical Adriamycin (40mg / 20ml, instillation after TUR. The first instillation was usually given 2 weeks after TUR and repeated biweekly for 5 months. (a total of 10 instillations). All data were analyzed and obtained the following results : Mean follow up was 20.6 months in the control group and 19.9 months in the study group. During the follow up period, percent of recurrences for control group was 63.6% (7 cases) compared to 37.5% (6 cases ) for the study group. Recurrent rate in another words, recurrences per 100 patients-month was 5.73 for controls ang 3.46 for the Adriamycin group, respectively. There appeared to be a close relationship between initial tumor grade, size and number and the trend of tumor recurrence. Although Adriamycin effect could not be strictly compared to both groups, it seemed to have a potential for reducing recurrence according to these conditions (grade, size, number). Toxicity was not systemic, but vesical irritability such as frequency, dysuria and hematuria were noticed in 31.3% (5 cases).
